A primer on Post-COVID-19 conditions and implications for clinical pharmacists.
David B CluckKelly L CovertJamie L WagnerDaniel B ChastainPublished in: Journal of the American College of Clinical Pharmacy : JACCP (2022)
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is largely viewed as an acute illness involving multiple organ systems. In the wake of the acute illness, many survivors fully recover and return to baseline, while others suffer from a wide range of lingering symptoms collectively known as "post-COVID conditions". The recognition of these conditions as a clinical entity represents the first step in developing a targeted plan for recovery and symptom mitigation. While interventions to directly minimize or reduce new, recurrent, or persistent symptoms are currently unknown, pharmacists can play a key role in optimizing management of these patients.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- liver failure
- end stage renal disease
- respiratory failure
- ejection fraction
- chronic kidney disease
- newly diagnosed
- drug induced
- young adults
- physical activity
- climate change
- peritoneal dialysis
- sleep quality
- depressive symptoms
- intensive care unit
- primary care
- patient reported outcomes
- hepatitis b virus